^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:Xtandi (enzalutamide) (Androgen receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC

    Excerpt:
    ...- Histologically confirmed HR-positive/HER2-negative disease based on the most recent biopsy before signing the informed consent....
    Trial ID:
    ARIANNA
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SABCS 2020
    Title:

    Sumo-modified androgen receptors support the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer

    Published date:
    11/17/2020
    Excerpt:
    Treatment with Enz alone or in combination with a SUMO inhibitor attenuates migration and metastatic phenotype of ET-R HR+ Bca.
    Secondary therapy:
    SUMO inhibitor